Q-omics provides the consensus-scored SOCS6P1 profile across patient tissues and cancer cell-line models. SOCS6P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, SOCS6P1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, SOCS6P1 RNA expression shows 7,166 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, THCA, and THYM as cancer lineages where SOCS6P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOCS6P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOCS6P1 survival associations across molecular data types. SOCS6P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOCS6P1 RNA expression–survival associations across cancer types. High SOCS6P1 expression shows unfavorable associations in CHOL, KIRP, READ, THYM, BRCA and PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify CHOL as the clearest survival context for SOCS6P1 RNA expression.
This table summarizes SOCS6P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SOCS6P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOCS6P1 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in PRAD, LIHC and ESCA. The THCA box plot shows higher SOCS6P1 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p < 0.001).
This table shows molecular features associated with SOCS6P1 in patient tissues and cancer cell lines. In patient samples, SOCS6P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
